Budget Amount *help |
¥394,420,000 (Direct Cost: ¥303,400,000、Indirect Cost: ¥91,020,000)
Fiscal Year 2018: ¥70,850,000 (Direct Cost: ¥54,500,000、Indirect Cost: ¥16,350,000)
Fiscal Year 2017: ¥64,220,000 (Direct Cost: ¥49,400,000、Indirect Cost: ¥14,820,000)
Fiscal Year 2016: ¥64,220,000 (Direct Cost: ¥49,400,000、Indirect Cost: ¥14,820,000)
Fiscal Year 2015: ¥71,370,000 (Direct Cost: ¥54,900,000、Indirect Cost: ¥16,470,000)
Fiscal Year 2014: ¥123,760,000 (Direct Cost: ¥95,200,000、Indirect Cost: ¥28,560,000)
|
Outline of Final Research Achievements |
A repeat-binding molecule suppressed the elongation of the repeat and induced the contraction. This significant discovery was proven by many chemical, biochemical, and pathological evidence. Furthermore, these studies demonstrated the possibility of treating neurodegenerative diseases with small molecules. These studies repeatedly pointed out the importance of drug development for nucleic acid-targeting with small molecules and also exemplify the development of such small molecules. We are confident that these studies stimulated Japanese pharmaceutical companies and accelerated their research on the small molecules targeting nucleic acids.
|